This priority review is specifically for adults and children with hemophilia A without FVIII inhibitors.
The new vial size is 3500 IU (international unit).
The data showed its hemophilia B investigational gene therapy candidate AMT-060 could be successfully delivered to patients with certain pre-existing antibodies.
Our dedicated providers and inspiring volunteers and advocates can be recognized with an Award of Excellence!
Investigators look to establish whether VWF levels increase as patients with VWD age, and if so, whether this can be associated with lower risk for bleeding.
"It has become my passion to make a difference for people throughout the world. We all need access to treatment and care and education.”
The overall annualized bleeding rate for all 15 participants was reduced by 98% to an annual rate of 0.2 bleeds per patient.
In the Phase III HAVEN 3 study, patients who received HEMLIBRA prophylaxis every week or every two weeks experienced a 96% and 97% reduction in treated bleeds.
Genentech informed NHF of an unrelated postmarketing fatality that has occurred in an elderly patient who received treatment with emicizumab- kxwh (Hemlibra) for acquired hemophilia A.
Most postpubertal girls and adolescents who experience heavy menstrual bleeding are not screened for von Willebrand disease (VWD), despite years of recommendations from the American College of Obstetricians and Gynecologists.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car